The assay is focused on developing lead drugs for parasitic protozoans of the Trypanosomatidae family that cause sleeping sickness, Chagas' disease, and Leishmania. The project aims to discover and optimize selective inhibitors of the glycolytic enzyme pyruvate kinase (PYK) from Trypanosoma brucei. This has been validated as a drug target, and a qHTS was performed against the MLSMR to discover inhibitors. The parasites are entirely dependent on glycolysis for ATP, making it a strong drug target. PYKs show significant differences from human counterparts, making it a promising area for drug development. Is the molecule effective to this assay?